Abstract
The two novel approaches recently introduced for the treatment of resistant hypertension, i.e. carotid baroreceptor stimulation and renal denervation, share a number of similarities but are also characterized by important differences. The similarities include the evidence that both interventions have as common pathophysiological background the state of sympathetic overdrive characterizing essential hypertension. In addition both procedures 1) are invasive, 2) exert in the short-term period clearcut blood pressure lowering effects and 3) still face a number of open questions, particularly related to the long-term blood pressure lowering effects, impact on end-organ damage and on cardiovascular events. The differences include the fact that two procedures act on distinct targets that trigger sympathetic activation and consequently blood pressure increase. In addition, only in the case of carotid baroreceptor stimulation the blood pressure effects can be easily assessed immediately following the implantation. Finally, the economic costs, metabolic effects and impact on vagal modulation of heart rate are different between the two interventions. This paper will provide a comparison of the background, effects and outcome of renal denervation and carotid baroreceptor stimulation, stressing whenever possible the clinical implications of the main features of the two interventions.
Keywords: Resistant hypertension, renal denervation, carotid baroreceptor stimulation, symapthetic activity, end organ damage.
Current Vascular Pharmacology
Title:Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Volume: 12 Issue: 1
Author(s): Guido Grassi, Gino Seravalle, Gianmaria Brambilla, Francesca Cesana, Cristina Giannattasio and Giuseppe Mancia
Affiliation:
Keywords: Resistant hypertension, renal denervation, carotid baroreceptor stimulation, symapthetic activity, end organ damage.
Abstract: The two novel approaches recently introduced for the treatment of resistant hypertension, i.e. carotid baroreceptor stimulation and renal denervation, share a number of similarities but are also characterized by important differences. The similarities include the evidence that both interventions have as common pathophysiological background the state of sympathetic overdrive characterizing essential hypertension. In addition both procedures 1) are invasive, 2) exert in the short-term period clearcut blood pressure lowering effects and 3) still face a number of open questions, particularly related to the long-term blood pressure lowering effects, impact on end-organ damage and on cardiovascular events. The differences include the fact that two procedures act on distinct targets that trigger sympathetic activation and consequently blood pressure increase. In addition, only in the case of carotid baroreceptor stimulation the blood pressure effects can be easily assessed immediately following the implantation. Finally, the economic costs, metabolic effects and impact on vagal modulation of heart rate are different between the two interventions. This paper will provide a comparison of the background, effects and outcome of renal denervation and carotid baroreceptor stimulation, stressing whenever possible the clinical implications of the main features of the two interventions.
Export Options
About this article
Cite this article as:
Grassi Guido, Seravalle Gino, Brambilla Gianmaria, Cesana Francesca, Giannattasio Cristina and Mancia Giuseppe, Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990142
DOI https://dx.doi.org/10.2174/15701611113119990142 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Retinopathy: Recent Updates on Different Biomarkers and Some Therapeutic Agents
Current Diabetes Reviews Volume Measurement in the Diagnosis of Mounier Kuhn Syndrome and an Unknown Accompanying Pathology: Pulmonary Artery Enlargement
Current Medical Imaging Editorial (Hot Topic: Marine Peptides: Emerging Perspectives for Pharmaceuticals)
Current Protein & Peptide Science Ivabradine: A Current Overview
Current Clinical Pharmacology Androgen Deficiency in Aging Male Questionnaire for the Clinical Detection of Testosterone Deficiency in a Population of Black Sub-Saharan African Men with Type 2 Diabetes Mellitus: Is it a Reliable Tool?
Current Diabetes Reviews Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase
Protein & Peptide Letters Aldosterone to Renin Ratio (ARR) in Clinical use, with Reference to the Primary Care Setting: ARR to Whom, When, How, What for?
Current Hypertension Reviews Modeling Cardiovascular Development: New Approaches are Making In Vitro En Vogue
Current Cardiology Reviews Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets The Application of Chitosan and Its Derivatives as Nanosized Carriers for the Delivery of Chemical Drugs and Genes or Proteins
Current Drug Targets A Link Between Hypertension and Atrial Fibrillation: Methods of Treatment and Prevention
Current Vascular Pharmacology The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice
Current Cardiology Reviews Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Research Progress on Pathogenesis of Obesity-Induced Insulin Resistance and Its Therapeutic Targets: PPARα/γ
Current Signal Transduction Therapy Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Antihypertensive Properties of Angiotensin-Converting Enzyme Inhibitors (ACEI) Independent of the Renin-Angiotensin System
Current Hypertension Reviews Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Functional Crosstalk Between β2-adrenoreceptor and Muscarinic Acetylcholine Receptor: Implications for Gene-Gene Interactions and Bronchodilatory Responses in Patients with Asthma and COPD
Current Pharmacogenomics and Personalized Medicine